HR Execs on the Move

Meadows Regional Medical Center

www.meadowsregional.org

 
Meadows Regional Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Meadows Regional Medical Center is based in Vidalia, GA. You can find more information on Meadows Regional Medical Center at www.meadowsregional.org
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

SNBL USA

SNBL USA is a part of the SNBL Group of companies and is a subsidiary of Shin Nippon Biomedical Laboratories (SNBL). As part of the SNBL Group, SNBL USA shares the corporate mission statement: We are committed to freeing patients from suffering by

Galileo Laboratories

Galileo Laboratories is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Navicure

Navicure has chosen to focus exclusively on the needs of practices and institutions performing physician billing.

Austen Riggs Center

Austen Riggs Center is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in West Stockbridge, MA. To find more information about Austen Riggs Center, please visit www.austenriggs.net

Kite Pharma

Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.